ArticleFrontiers in oncology2024

Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?

Merve Keskinkilic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.